IP Library › Granted Patent US 12,285,451
Granted Patent B2
US 12,285,451 · App. 17/854,371 · Granted Apr 29, 2025

Means and methods for AAV gene therapy in humans

Inventors: Bart Antonius Nijmeijer (Amsterdam, NL); Valerie Ferreira (Amsterdam, NL)
Assignee: uniQure IP B.V.
A61K35/761A61K9/0019A61K48/0008A61K48/0058A61K48/0083A61P7/04C12N15/62C12N15/86C07K14/755C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,451
App. No.
17/854,371
Granted
Apr 29, 2025
Kind
B2
Abstract

The present invention relates to means and method for AAV based gene therapies in humans. In particular, the present invention relates to the treatment of human patients that may be suspected to have antibodies directed against the AAV intended for use in the treatment.

Claims (13)

1. A method of treating a human disease comprising administering an effective amount of an AAV5 gene therapy vector to a human in need thereof;

wherein said human is subjected to a pre-screening with an assay to determine anti-AAV5 antibodies;

and wherein said human has not been subjected to a medical treatment with an AAV5 gene therapy vector prior to said medical treatment, said human having an anti-AAV5 antibody level of at most the 100 th percentile of anti-AAV5 antibody levels as observed in the human population not before treated with an AAV5 vector, wherein said human tested positive for anti-AAV5 bodies.

2. The method of treating a human disease in accordance with claim 1 , wherein said human has an anti-AAV5 antibody level of at most the 95th percentile of anti-AAV5 antibody levels as observed in the human population.

3. The method of treating a human disease in accordance with claim 1 , wherein said AAV5 gene therapy vector is administered at a dosage of at least 10 12 capsids/kg.

4. The method of treating a human disease in accordance with claim 1 , wherein said AAV5 gene therapy vector is administered at a dosage of at least 10 12 gc/kg of body weight.

5. The method of treating a human disease in accordance with claim 1 , wherein said AAV5 gene therapy vector is administered to a human having Hemophilia A or Hemophilia B.

6. The method of treating a human disease in accordance with claim 1 , wherein said AAV5 gene therapy vector is administered to a human having Hemophilia, wherein the AAV5 gene therapy vector encodes a FIX protein or variant thereof.

7. The method of treating a human disease in accordance with claim 1 , wherein said method comprises administering the AAV5 gene therapy vector into the bloodstream.

8. The method of treating a human disease in accordance with claim 5 , wherein said method comprises administering the AAV5 gene therapy vector into the bloodstream.

9. The method of treating a human disease in accordance with claim 6 , wherein said method comprises administering the AAV5 gene therapy vector into the bloodstream.

10. The method of treating a human disease in accordance with claim 7 , wherein said method comprises delivery of the AAV5 gene therapy vector to the liver via the bloodstream.

11. The method of treating a human disease in accordance with claim 1 , wherein said AAV5 gene therapy vector is produced in insect cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: NIJMEIJER, BART ANTONIUS; FERREIRA, VALERIE
To: UNIQURE IP B.V.
Reel/Frame 060369/0610 →
Priority Claims (1)
EP 17180601 · Jul 10, 2017 · regional
Continuity (2)
Continuation 16031906 · Jul 10, 2018
Related Publication 20220395545A1 · Dec 15, 2022
References Cited (18)
US 10512675B2 · Bunting · 2019 [cited by applicant]
WO 2015137802A1 · 2015 [cited by applicant]
WO 2016210170A1 · 2016 [cited by applicant]
Leebeek et al (Blood, Dec. 2, 2016, vol. 128, No. 22). (Year: 2016). [cited by examiner]
Naso (BioDrugs, Jul. 1, 2017, vol. 31, pp. 317-334). (Year: 2017). [cited by examiner]
BioMarin Pharmaceutical, “A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Hemoph… [cited by applicant]
Boutin et al., “Prevalence of Serum lgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors”, Human Gene Th… [cited by applicant]
Dolgin, Elie, “Early clinical data raise the bar for hemophilia gene therapies”, Nature Biotechnology, 2016, 34(10):999-1001. [cited by applicant]
European Extended Search Report for Application No. 17180601.1 dated Dec. 1, 2017. (9 pages). [cited by applicant]
Hildinger et al., “Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer”, Journal of Virology, 2001, 75(3):6199-6203. [cited by applicant]
Leebeek et al., “Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B”, Blood, 2016, 128:2314. (6 pages). [cited by applicant]
Mingozzi et al., “Immune responses to AAV vectors; overcoming barriers to successful gene therapy”, Blood, 2013, 122(1):23-36. [cited by applicant]
Nathwani et al., “Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates”, Blood, 2007, 10… [cited by applicant]
Sen et al., “Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy”, Scientific Reports 3, Article No. 1832, 2013. (6 pages). [cited by applicant]
UniQuire Biopharma B.V., “Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B”, ClinicalTrials,gov, Feb. 3, 2017, retrieved from the internet: URL:https://clinicaltrials.gov/ct2/show/NCT02396342. (7 pages). [cited by applicant]
Long, Brian R., et al. “The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy.” Molecular Therapy Methods & Clinical Development 13 (2019): 440-452. [cited by applicant]
Srivastava, A., 2016. In vivo tissue-tropism of adeno-associated viral vectors. Current opinion in virology, 21, pp. 75-80. [cited by applicant]
Manno, C.S., Chew, A.J., Hutchison, S., Larson, p. J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M. and Couto, L.B., 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patien… [cited by applicant]